Join the 'Pancrecarb MS-16' group to help and get support from people like you.
Pancrecarb MS-16 News
Posted 10 Jan 2017 by Drugs.com
MONDAY, Jan. 9, 2017 – Children with Crohn's disease and ulcerative colitis may be able to achieve relief without medications by eating a special diet, a small study suggests. The diet includes non-processed foods, such as fruits, vegetables, meats and nuts. Over 12 weeks, the diet appeared to ease all signs of these inflammatory bowel diseases in eight of the 10 affected children, researchers report. "The study shows that without other intervention, other changes, we can improve individuals' clinical as well as laboratory markers," said study author Dr. David Suskind. He's a professor of pediatrics and director of clinical gastroenterology at Seattle Children's Hospital. "I'm not surprised," Suskind added, "primarily because preliminary studies ... opened our eyes to the idea that diet had an impact." Inflammatory bowel disease (IBD) affects about 1.6 million Americans, according to ... Read more
Related support groups: Crohn's Disease, Colitis, Dietary Supplementation, Ulcerative Colitis, Asacol, Crohn's Disease - Maintenance, Creon, Inflammatory Bowel Disease, Sulfasalazine, Ulcerative Colitis - Active, Pentasa, Lialda, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lactaid, Apriso, Mesalamine, Pancrease, Zenpep, Canasa
Posted 18 May 2012 by Drugs.com
BETHLEHEM, Pa., May 18, 2012 /PRNewswire/ – Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for Pertzye, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. Pertzye is a unique pancreatic enzyme product containing bicarbonate-buffered enteric-coated microspheres and is protected by several U.S. and international patents. The Pertzye formulation was previously marketed by DCI for over a decade under the trade name Pancrecarb MS-16. Dr. Tibor Sipos, President and Chief Scientific Officer at DCI stated, "The approval of Pertzye represents a significant milestone for DCI. This achievement confirms our commitment to the continued development of products vital to the well-being of patients living with chronic diseases." T ... Read more